Verastem (VSTM) Gross Profit (2018 - 2026)

Verastem (VSTM) posted quarterly Gross Profit of $15.9 million for Q1 2026, up 6.54% quarter-over-quarter from $14.9 million in Q4 2025.

Analysis

Verastem (VSTM) Gross Profit (2018 - 2026) Analysis & Trends

Verastem's Gross Profit history runs 5 years deep, the most recent figure standing at $15.9 million for Q1 2026.

In Q1 2026, Gross Profit changed N/A year-over-year to $15.9 million; the TTM figure through Mar 2026 stood at $42.2 million (changed N/A YoY), while the FY2025 annual figure was $26.3 million, changed N/A from the prior year.
Gross Profit for Q1 2026 stood at $15.9 million, up from $14.9 million in the prior quarter.
The five-year high for Gross Profit was $15.9 million in Q1 2026, with the low at $1.8 million in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.77 Bn	130.92 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.51 Bn	77.52 Bn	3.93 Bn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn
4	Moderna	58.20 Bn	53.06 Bn	52.00 Mn
5	Revolution Medicines	44.04 Bn	44.04 Bn	-
6	BeOne Medicines	39.99 Bn	34.89 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn
8	Royalty Pharma	28.40 Bn	27.56 Bn	-
9	Insmed	27.44 Bn	26.28 Bn	358.27 Mn
10	Verastem	800.93 Mn	664.58 Mn	36.32 Mn

Historic Data

Download Data